On Wednesday, the Brazilian Health Regulatory Agency (Anvisa) approved the registration of a multidose variant of Mounjaro, a medication designed to treat type 2 diabetes and aid weight management in individuals with obesity or overweight issues. This newly approved version, produced by the American pharmaceutical company Eli Lilly, utilizes a reusable applicator, setting it apart from the single-use disposable pens currently available on the market. The approval marks a significant advancement in the accessibility and administration of diabetes treatment in Brazil.

According to Dr. Felipe Henning Gaia Duarte, an endocrinologist and president of the São Paulo Regional Society of Endocrinology and Metabolism, the new formulation will facilitate treatment, allowing patients to take their weekly doses more conveniently. Previously, patients needed to purchase multiple single-use pens, each containing only one dose. The new system permits four applications from a single vial, which is expected to be more efficient and user-friendly.

While a prescription is mandatory for purchase, specific pricing details for the Mounjaro multidose version in Brazil are yet to be announced. This approval by Anvisa not only enhances treatment options for diabetes and obesity but also signals a positive development in the ongoing efforts to better manage these chronic health conditions in Brazil, a country facing rising rates of both diabetes and obesity among its population.